Identification of Patients with Pentosan Polysulfate Sodium-Associated Maculopathy through Screening of the Electronic Medical Record at an Academic Center

Table 1

Demographics and pentosan polysulfate sodium exposure history for patients who had an eye exam (n = 96) and patient with maculopathy from outside referral (n = 1).

	PPS patients without maculopathy (n = 93 patients)	PPS patients with maculopathy (n = 4 patients)
Age, mean, years (median, range)	63 (67, 22–94)	73 (72, 67–81)
Race, no. (%)
White	69 (74)	3 (75)
Black	1 (1)	0 (0)
Asian/Indian	10 (11)	0 (0)
Middle Eastern	0 (0)	0 (0)
Hispanic	3 (3)	0 (0)
Native American	1 (1)	0 (0)
Unknown	8 (9)	1 (25)
Mixed	1 (1)	0 (0)
Sex, no. (%)
Male	12 (13)	0 (0)
Female	81 (87)	4 (100)
BMI, mean, kg/m ^ 2 (median, range)	28 (27, 18–51)	23 (23, 21–25)
Interval from date of IC diagnosis until now, mean, years (median, range)	9 (8, 1–43)	14 (14, 6–20)
Duration of PPS use, mean, years (median, range)	3 (1, 0–13)	12 (11, 6–19)
PPS daily dose, mean, mg (median, range)	295 (30, 100–400)	394 (400, 378–400)
PPS daily dose by body weight, mean, mg/kg (median, range)	4 (4, 2–8)	7 (6, 5–8)
Cumulative PPS exposure to date, mean, g (median, range)	295 (113, 2–1371)	1701 (1607, 812–2776)
BCVA OD logarithmic mean (median, range)	0.19 (0.10, 0.00–0.88)	0.6 (0.30, 0.00–1.90)
Snellen equivalent mean (median, range)	20/30 (20/25, 20/20–20/150)	20/80 (20/40–20/1600)
BCVA OS logarithmic mean (median, range)	0.16 (0.10, 0.00–0.54)	0.7 (0.40, 0.10–1.90)
Snellen equivalent mean (median, range)	20/30 (20/25, 20/20–20/70)	20/100 (20/50, 20/25–20/1600)

^∗Patient 4 changed daily doses during treatment period; 378 mg represents the equivalent daily dose during the treatment period.